BELOTECAN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H27N3O4.ClH
Molecular Weight	469.961
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O

InChI

InChIKey=SJKBXKKZBKCHET-UQIIZPHYSA-N

InChI=1S/C25H27N3O4.ClH/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22;/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3;1H/t25-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C25H27N3O4
Molecular Weight	433.4996
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9875499

Belotecan is a semisynthetic analogue of camptothecin containing a 2-(N-isopropylamino) ethyl group linkage at position C-7 of the camptothecin ring. It stabilizes the complex formed between topoisomerase I and DNA, thereby preventing the religation of DNA breaks. This leads to an inhibition of DNA replication and triggers apoptotic cell death. Belotecan was approved in Korea under the name Camtobell for the treatment of patients with ovarian and small cell lung cancers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase 1 16 Target ID: P11387\|\|\|Q9UJN0 Gene ID: 7150.0 Gene Symbol: TOP1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9875499	Inhibitor 8504		0.275 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ovarian cancer 160 Sources: http://www.kpbma.or.kr/attach/2016%20%EC%A0%9C%EC%95%BD%ED%98%91%ED%9A%8C%20%EC%98%81%EB%AC%B8%EB%94%94%EB%A0%89%ED%86%A0%EB%A6%AC_%EB%82%B4%EC%A7%80%EC%B5%9C%EC%A2%85.pdf	Primary		Approved 8583	CAMTOBELL Approved Use Ovarian cancer, SCLC Launch Date 2003
Small-cell lung cancer 41 Sources: http://www.kpbma.or.kr/attach/2016%20%EC%A0%9C%EC%95%BD%ED%98%91%ED%9A%8C%20%EC%98%81%EB%AC%B8%EB%94%94%EB%A0%89%ED%86%A0%EB%A6%AC_%EB%82%B4%EC%A7%80%EC%B5%9C%EC%A2%85.pdf	Primary		Approved 8583	CAMTOBELL Approved Use Ovarian cancer, SCLC Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
58.23 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² single, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
47.37 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² 1 times / day multiple, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
66.47 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² single, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
70.78 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² 1 times / day multiple, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
91.81 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² single, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
75.69 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² 1 times / day multiple, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
91.78 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² single, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
86.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² 1 times / day multiple, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
117.32 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² single, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
102.74 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² 1 times / day multiple, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
111.72 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² single, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
115.85 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² 1 times / day multiple, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
155.64 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² single, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
148.06 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² 1 times / day multiple, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
179.25 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² single, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
182.16 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² 1 times / day multiple, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
8.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² single, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.4 mg/m² 1 times / day multiple, intravenous dose: 0.4 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² single, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.45 mg/m² 1 times / day multiple, intravenous dose: 0.45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.55 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² single, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.74 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.5 mg/m² 1 times / day multiple, intravenous dose: 0.5 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² single, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17947485/	0.55 mg/m² 1 times / day multiple, intravenous dose: 0.55 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: CISPLATIN	CISPLATIN	BELOTECAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.55 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 0.55 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.55 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	DLT: Febrile neutropenia... Dose limiting toxicities: Febrile neutropenia (40%) Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/
0.5 mg/m2 1 times / day multiple, intravenous MTD Dose: 0.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.5 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	DLT: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/
0.5 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 0.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.5 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33191408/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33191408/	Disc. AE: Pneumonia... AEs leading to discontinuation/dose reduction: Pneumonia (grade 5, 1.25%) Sources: https://pubmed.ncbi.nlm.nih.gov/33191408/

AEs

AE	Significance	Dose	Population
Febrile neutropenia	40% DLT	0.55 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 0.55 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.55 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/
Thrombocytopenia	16.7% DLT	0.5 mg/m2 1 times / day multiple, intravenous MTD Dose: 0.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.5 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17947485/
Pneumonia	grade 5, 1.25% Disc. AE	0.5 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 0.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 0.5 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33191408/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33191408/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	BCRP 697 P-gp 2052 MRP2 252

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18654741/	yes
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18654741/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18654741/	yes

PubMed

Title	Date	PubMed
Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.	2014-01	24102892
Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose.	2010-11	20600456
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.	2010-10	20138389
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.	2010-06	20566426
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.	2010-06	19745693
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.	2010-06	19683359
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.	2010-02	20178532
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.	2010-01-01	19904804
Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay.	2009-12	19966525
Gateways to clinical trials.	2009-11	20094643
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.	2009-11	19675541
Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.	2009-10	19794997
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.	2009-10	19552531
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.	2009-08	19723113
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.	2009-06	19424618
Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.	2009-03	18715816
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.	2009-02-15	19190127
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.	2008-11	18654741
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.	2008-06	18405948
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.	2008-01	17823384
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.	2007-12-01	18056203
Effect of probenecid on the biliary excretion of belotecan.	2007-11	18087819
A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.	2007-10-15	17947485
STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.	2007-08-19	17695551
Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.	2007-02	16896929
Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats.	2006-08	16814440
The synergism between Belotecan and cisplatin in gastric cancer.	2006	19771277
4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs.	2005-05	15778009
Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits.	2005	15720034
Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats.	2004-12	15546689
Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats.	2004-01-22	15808800
CKD-602. Chong Kun Dang.	2003-12	14763132
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.	2003-01-25	12504179
Safety pharmacology of CKD-602, a novel anticancer agent.	2003	12785124
In vitro pharmacodynamics of CKD-602 in HT-29 cells.	2002-10	12433211
Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics.	2002-06-04	12052706

Patents

Sample Use Guides

In Vivo Use Guide

Small cell lung cancer: 0.5mg/m2/day for day 1 to 4. Ovarian cancer: 0.5mg/m2 IV days 1, 2, 3, 4, 5 of each 21 day cycle until 6 cycle or disease progression.

Route of Administration: Intravenous

In Vitro Use Guide

In a cell viability assay, human glioblastoma cell lines (U87 MG, U251 MG, U343 MG, LN229) were plated in 96-well plates at a density of 2x10(3) cells/well (100 ul). In each experimental set, cells were plated in quadruplicate and were treated with different concentrations (0.05, 0.1, 0.2, 0.5, 1, 2, 5 uM) of belotecan for 24, 48 and 72 h. The IC50 values were 84.66 nM for U87 MG cells, 29.13 nM for U343 MG, 14.57 nM for U251 MG cells and 9.07 nM for LN229 cells at 48 h after treatment.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:43 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:43 GMT 2025`
Record UNII	01DZ4127G7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BELOTECAN HYDROCHLORIDE [MI]

Preferred Name

English

BELOTECAN HYDROCHLORIDE

Official Name

English

BELOTECAN HCL

Common Name

English

BELOTECAN HYDROCHLORIDE [MART.]

Common Name

English

BELOTECAN HYDROCHLORIDE [USAN]

Common Name

English

1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE,4-ETHYL-4-HYDROXY-11(2-((1METHYLETHYL)-MONOHYDROCHLORIDE, (4S)-

Common Name

English

(4S)-4-ETHYL-4-HYDROXY-11-(2-((1-METHYLETHYL)AMINO)ETHYL)-1,12-DIHYDRO-14H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H)-DIONEHYDRODCHLORIDE

Common Name

English

CKD-602

Code

English

Belotecan hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2843